Who are Anti-tumor necrosis factor alpha agents's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, Infliximab [infliximab biosimilar 3], Infliximab-Dyyb, daclizumab, infliximab, Adalimumab with methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-tumor-necrosis-factor-alpha-agents.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-tumor necrosis factor alpha agents — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-tumor necrosis factor alpha agents (Anti-tumor necrosis factor alpha agents) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-TNF agents. Area: Immunology.

phase 2 Anti-TNF agents TNF-alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-tumor necrosis factor alpha agents (Anti-tumor necrosis factor alpha agents) — El-Hussuna, Alaa, M.D.. Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-tumor necrosis factor alpha agents TARGET	Anti-tumor necrosis factor alpha agents	El-Hussuna, Alaa, M.D.	phase 2	Anti-TNF agents	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
Infliximab-Dyyb	Infliximab-Dyyb	Asan Medical Center	marketed	TNF-alpha inhibitor; monoclonal antibody	TNF-alpha (TNFα)
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-TNF agents class)

El-Hussuna, Alaa, M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-tumor necrosis factor alpha agents — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tumor-necrosis-factor-alpha-agents. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab